Search research articles
Contact Us
Filters
Showing results (71-80 of 82) with videos related to
Page
of 9
Sort By:
Circulation Research
|
February 26, 2014
Autologous mesenchymal stem cells produce concordant improvements in regional function, tissue perfusion, and fibrotic burden when administered to patients undergoing coronary artery bypass grafting: The Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS) trial
Vasileios Karantalis, Darcy L DiFede, Gary Gerstenblith, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
May 21, 2008
HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide
Leo Luznik, Paul V O'Donnell, Heather J Symons, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
November 9, 2021
Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center Experience
Alexander Ambinder, Matthew Smith, Hua-Ling Tsai, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
February 17, 2018
Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non-First-Degree Related Donors
Hany Elmariah, Yvette L Kasamon, Marianna Zahurak, et al.
Transplantation and Cellular Therapy
|
February 14, 2022
Post-Transplantation Cyclophosphamide-Based Graft- versus-Host Disease Prophylaxis with Nonmyeloablative Conditioning for Blood or Marrow Transplantation for Myelofibrosis
Tania Jain, Hua-Ling Tsai, Amy E DeZern, et al.
Blood
|
October 16, 2014
Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS
Christopher G Kanakry, Hua-Ling Tsai, Javier Bolaños-Meade, et al.
Blood Advances
|
September 29, 2021
FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology
Cirino Botta, Catarina Maia, Juan-José Garcés, et al.
Haematologica
|
November 16, 2016
Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide
Shannon R McCurdy, Yvette L Kasamon, Christopher G Kanakry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 12, 2015
Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults
Yvette L Kasamon, Javier Bolaños-Meade, Gabrielle T Prince, et al.
Blood
|
March 28, 2015
Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide
Shannon R McCurdy, Jennifer A Kanakry, Margaret M Showel, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 82) with videos related to
Sort By:
Page
of 9
Circulation Research
|
February 26, 2014
Autologous mesenchymal stem cells produce concordant improvements in regional function, tissue perfusion, and fibrotic burden when administered to patients undergoing coronary artery bypass grafting: The Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS) trial
Vasileios Karantalis, Darcy L DiFede, Gary Gerstenblith, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
May 21, 2008
HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide
Leo Luznik, Paul V O'Donnell, Heather J Symons, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
November 9, 2021
Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center Experience
Alexander Ambinder, Matthew Smith, Hua-Ling Tsai, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
February 17, 2018
Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non-First-Degree Related Donors
Hany Elmariah, Yvette L Kasamon, Marianna Zahurak, et al.
Transplantation and Cellular Therapy
|
February 14, 2022
Post-Transplantation Cyclophosphamide-Based Graft- versus-Host Disease Prophylaxis with Nonmyeloablative Conditioning for Blood or Marrow Transplantation for Myelofibrosis
Tania Jain, Hua-Ling Tsai, Amy E DeZern, et al.
Blood
|
October 16, 2014
Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS
Christopher G Kanakry, Hua-Ling Tsai, Javier Bolaños-Meade, et al.
Blood Advances
|
September 29, 2021
FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology
Cirino Botta, Catarina Maia, Juan-José Garcés, et al.
Haematologica
|
November 16, 2016
Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide
Shannon R McCurdy, Yvette L Kasamon, Christopher G Kanakry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 12, 2015
Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults
Yvette L Kasamon, Javier Bolaños-Meade, Gabrielle T Prince, et al.
Blood
|
March 28, 2015
Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide
Shannon R McCurdy, Jennifer A Kanakry, Margaret M Showel, et al.
Page
of 9